


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:44Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406654" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406654</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>aac</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406654</article-id><article-id pub-id-type="pmcid-ver">PMC12406654.1</article-id><article-id pub-id-type="pmcaid">12406654</article-id><article-id pub-id-type="pmcaiid">12406654</article-id><article-id pub-id-type="pmid">40762485</article-id><article-id pub-id-type="doi">10.1128/aac.00087-25</article-id><article-id pub-id-type="publisher-id">aac00087-25</article-id><article-id pub-id-type="publisher-id">aac.00087-25</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Therapeutics</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics and safety of single and repeat doses of ceftibuten in healthy participants: a phase 1 dose escalation study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dorr</surname><given-names initials="MB">Mary Beth</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-4989-4896</contrib-id><name name-style="western"><surname>de Oliveira</surname><given-names initials="CF">Carlos Fernando</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>van de Wetering</surname><given-names initials="J">Jeroen</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lowe</surname><given-names initials="K">Kathryn</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sabato</surname><given-names initials="P">Philip</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Winchell</surname><given-names initials="G">Gregory</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="H">Hongzi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5906-2818</contrib-id><name name-style="western"><surname>McGovern</surname><given-names initials="PC">Paul C.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role><email>mcgovern@venatorx.com</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>VenatoRx Pharmaceuticals Inc</institution></institution-wrap>, <city>Malvern</city>, <state>Pennsylvania</state>, <country>USA</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>PRA Health Sciences</institution><institution-id institution-id-type="ringgold">107593</institution-id><institution-id institution-id-type="ror">https://ror.org/02k5t6c64</institution-id></institution-wrap>, <city>Groningen</city>, <country>the Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>Winchell Pharma Consulting, LLC</institution></institution-wrap>, <city>Norristown</city>, <state>Pennsylvania</state>, <country>USA</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Doernberg</surname><given-names initials="S">Sarah</given-names></name><aff><institution-wrap><institution>University of California San Francisco</institution></institution-wrap>, <city>San Francisco</city>, <state>California</state>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Paul C. McGovern, <email xlink:href="mailto:mcgovern@venatorx.com">mcgovern@venatorx.com</email></corresp><fn fn-type="COI-statement"><p>K.L. and P.C.M. are employees of Venatorx Pharmaceuticals, Inc., Malvern, PA. M.B.D., C.F.O., P.S., and H.C. were employees of Venatorx Pharmaceuticals, Inc., at the time this work was conducted. G.W. is the principal of Winchell Pharma Consulting, LLC, and performed work as a paid contractor for Venatorx Pharmaceuticals, Inc. J.W. is an employee of ICON plc (formerly PRA Health Sciences).</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>9</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>8</month><year>2025</year></pub-date><volume>69</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496152</issue-id><elocation-id>e00087-25</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Dorr et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Dorr et al.</copyright-holder><ali:free_to_read start_date="2025-08-05"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="aac.00087-25.pdf"/><self-uri content-type="pdf" xlink:href="aac.00087-25.pdf"/><related-article related-article-type="companion" xml:lang="en" xlink:title="research-article" journal-id="Antimicrob Agents Chemother" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12406652"><article-title>Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers</article-title><volume>69</volume><issue>9</issue><date><day>5</day><month>8</month><year>2025</year></date><elocation-id>e00210-25</elocation-id><source>Antimicrobial Agents and Chemotherapy</source><pub-id pub-id-type="doi">10.1128/aac.00210-25</pub-id><pub-id pub-id-type="pmcid">PMC12406652</pub-id><pub-id pub-id-type="pmid">40762486</pub-id></related-article><abstract abstract-type="primary"><title>ABSTRACT</title><p>Ledaborbactam etzadroxil, the prodrug of the active &#946;-lactamase inhibitor ledaborbactam, is being developed in combination with ceftibuten to treat serious infections caused by drug-resistant Enterobacterales. This study evaluated the safety and pharmacokinetics of ceftibuten in healthy adults at anticipated higher doses required, in combination with ledaborbactam etzadroxil, to treat Enterobacterales infections. Thirty-six participants (<italic toggle="yes">n</italic> = 12 per cohort [ceftibuten <italic toggle="yes">n</italic> = 9, placebo <italic toggle="yes">n</italic> = 3]) received a single oral dose of ceftibuten (400, 800, or 1,200 mg) or matched placebo on day 1. Following a one-day washout, the same participants received repeat oral doses of ceftibuten (400 mg once daily, 400 mg every 12 hours [q12h], or 400 mg q8h) for 10 days. Of the 36 participants, 25 (ceftibuten 67%, placebo 78%) reported 65 treatment-emergent adverse events (TEAEs). Nausea (22%), headache (15%), and fatigue (15%) were the most reported TEAEs among ceftibuten-treated participants. No participant experienced serious adverse events or discontinuations due to TEAEs. In both single- and multiple-dose cohorts, cis-ceftibuten isomer exposure was dose-proportional for areas under the curve (AUCs) but less than dose-proportional for maximum concentrations (<italic toggle="yes">C</italic><sub>max</sub>). Low levels of cis-ceftibuten accumulation were observed at steady state, with accumulation ratios of 1.06, 1.09, and 1.24 for the 400 mg once daily, q12h, and q8h cohorts, respectively. Cis-ceftibuten and trans-ceftibuten recovery in urine was 47% and 6%, respectively, following a single dose of 1,200 mg.</p><sec><title>CLINICAL TRIALS</title><p>This study is registered with ClinicalTrials.gov as <related-object source-type="clinical-trials-registry" source-id-type="registry-name" source-id="ClinicalTrials.gov" document-id="NCT04314206" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/study/NCT04314206" id="RO1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04314206">NCT04314206</ext-link></related-object>.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>ceftibuten</kwd><kwd>pharmacokinetics</kwd><kwd>clinical trial, phase 1</kwd><kwd>drug safety</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>National Institute of Allergy and Infectious Diseases</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id></institution-wrap></funding-source><award-id>HHSN272201600029C</award-id><principal-award-recipient><name name-style="western"><surname>Dorr</surname><given-names>Mary Beth</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>Carlos Fernando</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>Kathryn</given-names></name><name name-style="western"><surname>Sabato</surname><given-names>Philip</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Hongzi</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>Paul C.</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><count count-type="authors" count="8"/><fig-count count="2"/><table-count count="3"/><equation-count count="0"/><ref-count count="12"/><page-count count="10"/><word-count count="5183"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Ceftibuten (Cedax), a broad-spectrum, third-generation, highly bioavailable oral cephalosporin antibiotic active against multiple gram-positive and -negative pathogens, was approved by the United States Food and Drug Administration in 1995 for the treatment of acute bacterial exacerbations of chronic bronchitis in adults and children aged 6 months or older (<xref rid="B1" ref-type="bibr">1</xref>) but is no longer available in the United States due to lack of a commercial market. Ceftibuten is approved and marketed in several European countries for the treatment of upper respiratory tract infections, lower respiratory tract infections, and urinary tract infections in adults and children over 6 months of age (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>The increasing global incidence of antibiotic resistance in Enterobacterales has created an unmet medical need for new oral agents to treat serious infections caused by extended-spectrum &#946;-lactamases (ESBLs) producing Enterobacterales and carbapenem-resistant Enterobacterales (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Due to its broad spectrum of activity, ceftibuten is an appealing candidate for development in combination with a &#946;-lactamase inhibitor that can restore activity against drug-resistant Enterobacterales. Ledaborbactam etzadroxil (previously VNRX-7145) is the prodrug of the active broad-spectrum &#946;-lactamase inhibitor ledaborbactam, which is capable of inhibiting serine &#946;-lactamases, including Ambler class A ESBLs and KPC-type carbapenemases, class C cephalosporinases, and class D oxacillinases, including the OXA-48 carbapenemase. Ceftibuten&#8211;ledaborbactam etzadroxil is being developed to address the unmet medical need for oral antibiotics to treat serious infections, including complicated urinary tract infections (cUTI). Here we report a phase 1 study conducted to evaluate the safety and pharmacokinetics (PK) of ceftibuten alone at doses higher than the approved 400 mg once-daily regimen, which will be required in combination with ledaborbactam etzadroxil for the treatment of Enterobacterales infections.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Disposition and participant demographics</title><p>A total of 36 participants (<italic toggle="yes">n</italic> = 12 per cohort [ceftibuten, <italic toggle="yes">n</italic> = 9; placebo, <italic toggle="yes">n</italic> = 3]) were enrolled in the study. Thirty-five participants completed the study per the protocol. One participant randomized to receive ceftibuten 1,200 mg on Day 1 and 400 mg every 8 hours (q8h) on Days 3&#8211;12 (1,200 mg cohort) discontinued study treatment and the study on Day 3 due to an adverse event (positive COVID-19 test result) and was not replaced.</p><p>Participant demographics and baseline characteristics were similar across cohorts (<xref rid="T1" ref-type="table">Table 1</xref>). Distributions of participant sex and weight varied across dose groups, with a lower mean weight of the subjects in the ceftibuten 1,200 mg cohort likely due to the distribution of females to males in that cohort (89% females in the ceftibuten 1,200 mg cohort versus relatively equal distribution in the other cohorts).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Participant demographics and baseline characteristics<xref rid="T1_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1"/><th align="left" valign="top" colspan="1" rowspan="1">Ceftibuten 400 mg cohort<break/>(<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">Ceftibuten 800 mg cohort (<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">Ceftibuten 1,200 mg cohort<break/>(<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">Pooled placebo cohorts<break/>(<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">Overall<break/>(<italic toggle="yes">n</italic> = 36)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Age, years, mean (SD)</td><td align="left" valign="top" colspan="1" rowspan="1">29.8 (5.3)</td><td align="left" valign="top" colspan="1" rowspan="1">28.2 (7.8)</td><td align="left" valign="top" colspan="1" rowspan="1">28.4 (9.7)</td><td align="left" valign="top" colspan="1" rowspan="1">24.3 (3.8)</td><td align="left" valign="top" colspan="1" rowspan="1">27.7 (7.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Male</td><td align="left" valign="top" colspan="1" rowspan="1">5 (56)</td><td align="left" valign="top" colspan="1" rowspan="1">4 (44)</td><td align="left" valign="top" colspan="1" rowspan="1">1 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">4 (44)</td><td align="left" valign="top" colspan="1" rowspan="1">14 (39)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Race</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;White</td><td align="left" valign="top" colspan="1" rowspan="1">6 (67)</td><td align="left" valign="top" colspan="1" rowspan="1">6 (67)</td><td align="left" valign="top" colspan="1" rowspan="1">6 (67)</td><td align="left" valign="top" colspan="1" rowspan="1">9 (100)</td><td align="left" valign="top" colspan="1" rowspan="1">27 (75)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Black or African American</td><td align="left" valign="top" colspan="1" rowspan="1">2 (22)</td><td align="left" valign="top" colspan="1" rowspan="1">1 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">3 (8)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Asian</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">2 (22)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">2 (6)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Other<xref rid="T1_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">2 (22)</td><td align="left" valign="top" colspan="1" rowspan="1">1 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">4 (11)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Not Hispanic or Latino</td><td align="left" valign="top" colspan="1" rowspan="1">9 (100)</td><td align="left" valign="top" colspan="1" rowspan="1">8 (89)</td><td align="left" valign="top" colspan="1" rowspan="1">9 (100)</td><td align="left" valign="top" colspan="1" rowspan="1">9 (100)</td><td align="left" valign="top" colspan="1" rowspan="1">35 (97)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Height, cm, mean (SD)</td><td align="left" valign="top" colspan="1" rowspan="1">177.9 (8.7)</td><td align="left" valign="top" colspan="1" rowspan="1">172.1 (12.9)</td><td align="left" valign="top" colspan="1" rowspan="1">168.0 (8.6)</td><td align="left" valign="top" colspan="1" rowspan="1">176.6 (6.5)</td><td align="left" valign="top" colspan="1" rowspan="1">173.6 (9.9)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Weight, kg, mean (SD)</td><td align="left" valign="top" colspan="1" rowspan="1">73.5 (8.1)</td><td align="left" valign="top" colspan="1" rowspan="1">70.80 (13.3)</td><td align="left" valign="top" colspan="1" rowspan="1">67.3 (7.6)</td><td align="left" valign="top" colspan="1" rowspan="1">73.2 (14.9)</td><td align="left" valign="top" colspan="1" rowspan="1">71.2 (11.2)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td align="left" valign="top" colspan="1" rowspan="1">23.3 (2.6)</td><td align="left" valign="top" colspan="1" rowspan="1">23.7 (1.6)</td><td align="left" valign="top" colspan="1" rowspan="1">23.8 (1.9)</td><td align="left" valign="top" colspan="1" rowspan="1">23.3 (3.4)</td><td align="left" valign="top" colspan="1" rowspan="1">23.5 (2.4)</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Except where otherwise specified, data are <italic toggle="yes">n</italic> (%). SD, standard deviation.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Participants categorized as &#8220;other&#8221; self-identified as &#8220;White and Black or African American&#8221; or as &#8220;White and Asian&#8221;.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Safety and tolerability</title><p>Treatment-emergent adverse events (TEAEs) were reported for 69% of participants (ceftibuten, 67%; placebo, 78%) (<xref rid="T2" ref-type="table">Table 2</xref>), across the combined single- and multiple-dose periods. In the single-dose period, 47% of participants (ceftibuten, 48%; placebo, 44%) experienced TEAEs. In the multiple-dose period, 50% of participants (ceftibuten, 48%; placebo, 56%) experienced TEAEs. No clinically relevant trends in TEAEs were identified between ceftibuten- and placebo-treated participants, nor among participants in the three ceftibuten dose cohorts. Gastrointestinal TEAEs were similar in the combined analysis, both between the pooled ceftibuten group (33%) and the placebo group (33%).</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Summary of treatment-emergent adverse events (TEAEs) occurring in &gt;10% of ceftibuten-exposed participants in the combined study periods<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1"/><th align="left" valign="top" colspan="1" rowspan="1">Pooled placebo cohorts (<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">Pooled ceftibuten cohorts (<italic toggle="yes">n</italic> = 27)</th><th align="left" valign="top" colspan="1" rowspan="1">Total (<italic toggle="yes">n</italic> = 36)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Participants with any TEAE</td><td align="left" valign="top" colspan="1" rowspan="1">7 (78)</td><td align="left" valign="top" colspan="1" rowspan="1">18 (67)</td><td align="left" valign="top" colspan="1" rowspan="1">25 (69)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">General disorders and administration site conditions</td><td align="left" valign="top" colspan="1" rowspan="1">6 (67)</td><td align="left" valign="top" colspan="1" rowspan="1">9 (33)</td><td align="left" valign="top" colspan="1" rowspan="1">15 (42)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Fatigue</td><td align="left" valign="top" colspan="1" rowspan="1">1 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">4 (15)</td><td align="left" valign="top" colspan="1" rowspan="1">5 (14)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Gastrointestinal disorders</td><td align="left" valign="top" colspan="1" rowspan="1">3 (33)</td><td align="left" valign="top" colspan="1" rowspan="1">9 (33)</td><td align="left" valign="top" colspan="1" rowspan="1">12 (33)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Nausea</td><td align="left" valign="top" colspan="1" rowspan="1">1 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">6 (22)</td><td align="left" valign="top" colspan="1" rowspan="1">7 (19)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Diarrhea</td><td align="left" valign="top" colspan="1" rowspan="1">2 (22)</td><td align="left" valign="top" colspan="1" rowspan="1">3 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">5 (14)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Abdominal pain</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">3 (11)</td><td align="left" valign="top" colspan="1" rowspan="1">3 (8)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Nervous system disorders</td><td align="left" valign="top" colspan="1" rowspan="1">3 (33)</td><td align="left" valign="top" colspan="1" rowspan="1">4 (15)</td><td align="left" valign="top" colspan="1" rowspan="1">7 (19)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Headache</td><td align="left" valign="top" colspan="1" rowspan="1">3 (33)</td><td align="left" valign="top" colspan="1" rowspan="1">4 (15)</td><td align="left" valign="top" colspan="1" rowspan="1">7 (19)</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Data are number (%) of participants.</p></fn></table-wrap-foot></table-wrap><p>The most common TEAEs among participants randomized to ceftibuten were nausea (22%), headache (15%), and fatigue (15%). All TEAEs were mild in severity, except for a moderate TEAE of headache in one placebo group participant. No clinically relevant changes in post-baseline vital signs or clinical laboratory, ECG, or physical examination findings were identified. No serious adverse events, drug-related study discontinuations, or deaths occurred.</p></sec><sec id="s2-3"><title>Pharmacokinetics</title><sec id="s2-3-1"><title>Single-dose pharmacokinetics</title><sec id="s2-3-1-1"><title>Plasma results</title><p>Arithmetic mean plasma concentration&#8211;time profiles for cis-ceftibuten and trans-ceftibuten following administration of single doses of ceftibuten 400&#8211;1,200 mg are shown in <xref rid="F1" ref-type="fig">Fig. 1</xref>. After administration of a single ceftibuten dose of 400&#8211;1,200 mg, for cis-ceftibuten, the geometric mean half-life (<italic toggle="yes">t</italic><sub>1/2</sub>) was 2.7&#8211;2.9 hours and geometric mean clearance (CL/F) was 5.30&#8211;5.91 L/h; for trans-ceftibuten, the geometric mean apparent <italic toggle="yes">t</italic><sub>1/2</sub> was 3.3&#8211;3.5 hours (<xref rid="T3" ref-type="table">Table 3</xref>). Cis-ceftibuten AUC<sub>inf</sub> increased dose proportionally, from 75.5 h&#183;&#181;g/mL in the ceftibuten 400 mg cohort to 203 h&#183;&#181;g/mL in the ceftibuten 1,200 mg cohort (slope, 0.90 [95% CI, 0.75&#8211;1.05]). <italic toggle="yes">C</italic><sub>max</sub> increased less than proportionally with increasing ceftibuten single doses (slope for cis-ceftibuten, 0.68 [95% CI, 0.57&#8211;0.80]).</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>Mean cis-ceftibuten (solid lines) and trans-ceftibuten (dashed lines) plasma concentrations versus time (linear scale) following single doses of ceftibuten. The inset shows a logarithmic concentration scale.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00087-25.f001.jpg"><alt-text>Plasma concentration-time curves for cis- and trans-ceftibutan after 400, 800, and 1,200 mg doses. Cis-ceftibuten levels rise dose-dependently, peaking near 2&#8211;3 h. Trans-ceftibuten remains consistently lower. Inset log scale shows differences over time.</alt-text></graphic></fig><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Geometric mean (% geometric coefficient of variation) of cis-ceftibuten and trans-ceftibuten pharmacokinetic parameters following single-dose (day 1) and multiple-dose (day 12) oral administration of ceftibuten</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Analyte</th><th align="left" valign="top" colspan="1" rowspan="1">Pharmacokinetic parameter<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1">Ceftibuten 400 mg cohort</th><th align="left" valign="top" colspan="1" rowspan="1">Ceftibuten 800 mg cohort</th><th align="left" valign="top" colspan="1" rowspan="1">Ceftibuten 1,200 mg cohort</th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1">Day 1<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1"/><th align="left" valign="top" colspan="1" rowspan="1">400 mg (<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">800 mg (<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">1,200 mg (<italic toggle="yes">n</italic> = 9)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Cis-ceftibuten</td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub> (&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">16.9 (14.5)</td><td align="left" valign="top" colspan="1" rowspan="1">27.5 (18.4)</td><td align="left" valign="top" colspan="1" rowspan="1">35.8 (16.3)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub>
<xref rid="T3_FN3" ref-type="table-fn">
<sup>
<italic toggle="yes">c</italic>
</sup>
</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2.5 (1.5&#8211;4.0)</td><td align="left" valign="top" colspan="1" rowspan="1">2.1 (1.5&#8211;4.0)</td><td align="left" valign="top" colspan="1" rowspan="1">2.5 (1.5&#8211;4.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td><td align="left" valign="top" colspan="1" rowspan="1">2.9 (22.0)</td><td align="left" valign="top" colspan="1" rowspan="1">2.8 (23.5)</td><td align="left" valign="top" colspan="1" rowspan="1">2.7 (22.7)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>inf</sub> (h&#183;&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">75.5 (21.0)</td><td align="left" valign="top" colspan="1" rowspan="1">143 (21.1)</td><td align="left" valign="top" colspan="1" rowspan="1">203 (22.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">CL/F (L/h)</td><td align="left" valign="top" colspan="1" rowspan="1">5.30 (21.0)</td><td align="left" valign="top" colspan="1" rowspan="1">5.61 (21.1)</td><td align="left" valign="top" colspan="1" rowspan="1">5.91 (22.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">Vz/F (L)</td><td align="left" valign="top" colspan="1" rowspan="1">22.1 (22.1)</td><td align="left" valign="top" colspan="1" rowspan="1">22.5 (24.3)</td><td align="left" valign="top" colspan="1" rowspan="1">22.6 (24.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Trans-ceftibuten</td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub> (&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">0.753 (18.7)</td><td align="left" valign="top" colspan="1" rowspan="1">1.45 (26.1)</td><td align="left" valign="top" colspan="1" rowspan="1">1.75 (18.9)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub>
<xref rid="T3_FN3" ref-type="table-fn">
<sup>
<italic toggle="yes">c</italic>
</sup>
</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">4.0 (2.0&#8211;5.0)</td><td align="left" valign="top" colspan="1" rowspan="1">4.0 (2.5&#8211;5.0)</td><td align="left" valign="top" colspan="1" rowspan="1">4.0 (3.0&#8211;5.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td><td align="left" valign="top" colspan="1" rowspan="1">3.52 (21.1)</td><td align="left" valign="top" colspan="1" rowspan="1">3.46 (15.6)</td><td align="left" valign="top" colspan="1" rowspan="1">3.30 (11.5)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>inf</sub> (h&#183;&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">5.64 (22.4)</td><td align="left" valign="top" colspan="1" rowspan="1">11.0 (26.5)</td><td align="left" valign="top" colspan="1" rowspan="1">14.2 (26.9)</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Day 12<xref rid="T3_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1"/><th align="left" valign="top" colspan="1" rowspan="1">400 mg once daily (<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">400 mg q12h<break/>(<italic toggle="yes">n</italic> = 9)<xref rid="T3_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1">400 mg q8h<break/>(<italic toggle="yes">n</italic> = 8)<xref rid="T3_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Cis-ceftibuten</td><td align="left" valign="top" colspan="1" rowspan="1">C<sub>max</sub> (&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">18.2 (19.1)</td><td align="left" valign="top" colspan="1" rowspan="1">19.1 (15.6)</td><td align="left" valign="top" colspan="1" rowspan="1">24.7 (15.5)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub>
<xref rid="T3_FN4" ref-type="table-fn">
<sup>
<italic toggle="yes">d</italic>
</sup>
</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2.0 (1.5&#8211;4.0)</td><td align="left" valign="top" colspan="1" rowspan="1">3.0 (2.0&#8211;5.0)</td><td align="left" valign="top" colspan="1" rowspan="1">3.0 (2.0&#8211;4.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td><td align="left" valign="top" colspan="1" rowspan="1">2.68 (14.2)</td><td align="left" valign="top" colspan="1" rowspan="1">2.52 (18.0)</td><td align="left" valign="top" colspan="1" rowspan="1">2.80 (26.7)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>tau</sub> (h&#183;&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">82.4 (19.3)</td><td align="left" valign="top" colspan="1" rowspan="1">85.9 (21.0)</td><td align="left" valign="top" colspan="1" rowspan="1">105 (16.3)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">R<sub>ac</sub><xref rid="T3_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1.06 (7.0)</td><td align="left" valign="top" colspan="1" rowspan="1">1.09 (18.8)</td><td align="left" valign="top" colspan="1" rowspan="1">1.24 (14.4)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">CLss/F</td><td align="left" valign="top" colspan="1" rowspan="1">4.86 (19.3)</td><td align="left" valign="top" colspan="1" rowspan="1">4.66 (21.0)</td><td align="left" valign="top" colspan="1" rowspan="1">3.81 (16.3)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">Vz/F</td><td align="left" valign="top" colspan="1" rowspan="1">18.8 (14.7)</td><td align="left" valign="top" colspan="1" rowspan="1">16.9 (16.3)</td><td align="left" valign="top" colspan="1" rowspan="1">15.4 (20.2)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Trans-ceftibuten</td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub> (&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">0.756 (21.1)</td><td align="left" valign="top" colspan="1" rowspan="1">0.970 (20.7)</td><td align="left" valign="top" colspan="1" rowspan="1">1.28 (27.4)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub>
<xref rid="T3_FN3" ref-type="table-fn">
<sup>
<italic toggle="yes">c</italic>
</sup>
</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">4.0 (2.7&#8211;6.0)</td><td align="left" valign="top" colspan="1" rowspan="1">4.0 (3.0&#8211;6.0)</td><td align="left" valign="top" colspan="1" rowspan="1">4.0 (3.0&#8211;5.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td><td align="left" valign="top" colspan="1" rowspan="1">3.57 (13.1)</td><td align="left" valign="top" colspan="1" rowspan="1">3.44 (13.3)</td><td align="left" valign="top" colspan="1" rowspan="1">3.61 (12.9)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>tau</sub> (h&#183;&#181;g/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">5.80 (23.2)</td><td align="left" valign="top" colspan="1" rowspan="1">6.25 (23.4)</td><td align="left" valign="top" colspan="1" rowspan="1">7.27 (28.8)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">R<sub>ac</sub><xref rid="T3_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1.01 (8.3)</td><td align="left" valign="top" colspan="1" rowspan="1">1.22 (24.4)</td><td align="left" valign="top" colspan="1" rowspan="1">1.56 (19.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="T3_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>AUC<sub>inf</sub>, area under the plasma concentration&#8211;time curve from time 0 through infinity; AUC<sub>tau</sub>, area under the concentration&#8211;time curve from time of administered dose through dosing interval (daily, tau = 24 hours; q12h, tau = 12 hours; q8h: tau = 8 hours); CL/F, apparent total plasma clearance (cis-isomer only); CLss/F, apparent total plasma clearance at steady state (cis-isomer only); <italic toggle="yes">C</italic><sub>max</sub>, maximum plasma concentration; <italic toggle="yes">t</italic><sub>1/2</sub>, terminal half-life; Vz/F, apparent volume of distribution at terminal phase (cis-isomer only).</p></fn><fn id="T3_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Parameters assessed following a single dose.</p></fn><fn id="T3_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p><italic toggle="yes">T</italic><sub>max</sub> values are median hours (range).</p></fn><fn id="T3_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>Parameters assessed on day 12, after 10 consecutive days of dosing.</p></fn><fn id="T3_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>q12h, every 12 hours; q8h, every 8 hours.</p></fn><fn id="T3_FN6"><label>
<sup>
<italic toggle="yes">f</italic>
</sup>
</label><p>R<sub>ac</sub> calculated as AUC<sub>tau</sub> day 12/day 3.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3-1-2"><title>Urine results</title><p>Urinary pharmacokinetics were assessed only in the ceftibuten 1,200 mg cohort. During the 24-hour period after a single dose on day 1, approximately 53% of the administered dose was recovered in urine: for cis-ceftibuten, Fe was 47.0%, and the mean renal clearance (CL<sub>R</sub>) was 2.76 L/h; for trans-ceftibuten, Fe was 6%, and mean CL<sub>R</sub> was 5.07 L/h.</p></sec></sec></sec><sec id="s2-4"><title>Multiple-dose pharmacokinetics</title><sec id="s2-4-1"><title>Plasma results</title><p>Arithmetic mean plasma concentration&#8211;time profiles for cis-ceftibuten and trans-ceftibuten following administration of multiple doses of ceftibuten mg are shown in <xref rid="F2" ref-type="fig">Fig. 2</xref>. In the multiple-dose period, steady-state plasma concentrations of cis-ceftibuten were reached within 1 day in all cohorts. The arithmetic mean trough concentrations increased with increasing dose. Across cohorts, on day 12, the cis-ceftibuten geometric mean <italic toggle="yes">t</italic><sub>1/2</sub> was 2.5&#8211;2.8 hours, and the geometric mean accumulation ratio (R<sub>ac</sub>) was 1.06&#8211;1.24 (<xref rid="T3" ref-type="table">Table 3</xref>). The geometric mean steady-state clearance (CL<sub>SS</sub>/F) decreased slightly with increasing total daily dose, from 4.86 L/h in the 400 mg once daily cohort to 3.81 L/h in the 400 mg q8h cohort. For trans-ceftibuten, across cohorts, the geometric mean <italic toggle="yes">t</italic><sub>1/2</sub> was 3.4&#8211;3.6 hours, and R<sub>ac</sub> was 1.01&#8211;1.56 (<xref rid="T3" ref-type="table">Table 3</xref>).</p><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Fig 2</label><caption><p>Mean cis-ceftibuten (solid lines) and trans-ceftibuten (dashed lines) plasma concentrations versus time (linear scale) following 10 days of dosing of ceftibuten. The inset shows a logarithmic concentration scale.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00087-25.f002.jpg"><alt-text>Plasma concentration-time profiles of cis- and trans-ceftibuten at 400&#8239;mg with varying dosing intervals. Cis-ceftibuten peaks highest with q8h dosing, followed by q12h and qd. Trans-ceftibuten levels remain consistently low across all regimens.</alt-text></graphic></fig></sec></sec><sec id="s2-5"><title>Protein binding</title><p>The geometric mean percentage of free drug (unbound to protein) was approximately 40% (range, 34.8%&#8211;44.5%) for both cis-ceftibuten and trans-ceftibuten and did not appear to be dose dependent.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>Ledaborbactam etzadroxil is an investigational broad-spectrum boronate &#946;-lactamase inhibitor with the potential to restore the activity of ceftibuten against Enterobacterales, including those producing serine &#946;-lactamases, and to address the need for oral antibiotics to treat drug-resistant Enterobacterales infections. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has set the ceftibuten susceptibility breakpoint for Enterobacterales at a minimum inhibitory concentration of &#8804;1 &#181;g/mL for infections originating in the urinary tract (<xref rid="B5" ref-type="bibr">5</xref>). In a collection of 1,066 urinary isolates, ceftibuten alone and ceftibuten-ledaborbactam inhibited 25.5% and 89.1%, respectively, of Enterobacterales with a MIC of &#8804;1 &#181;g/mL (<xref rid="B6" ref-type="bibr">6</xref>). Ceftibuten-ledaborbactam also inhibited 89.7%, 98.3%, and 54.1% of multidrug-resistant, phenotypic ESBL, and carbapenem-nonsusceptible Enterobacterales, respectively (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>The safety findings of this study indicated that single doses of ceftibuten up to 1,200 mg and multiple doses up to 400 mg q8h for 10 days were safe and well tolerated, with a consistent safety profile at doses exceeding the approved 400 mg daily dose. The known safety profile for ceftibuten includes the following common (&gt;1%) adverse reactions: nausea (4%), headache (3%), diarrhea (3%), dyspepsia (2%), dizziness (1%), abdominal pain (1%), and vomiting (1%) (<xref rid="B1" ref-type="bibr">1</xref>). With the exception of dizziness, all these commonly labeled adverse reactions were reported for participants in the ceftibuten cohorts of the current study. An important observation was that although gastrointestinal adverse events predominate among the labeled adverse reactions and the adverse events reported in this study, the incidence of gastrointestinal TEAEs did not increase at ceftibuten doses higher than 400 mg daily when dosed for 10 days.</p><p>The vast majority of ceftibuten that is dosed is cis-ceftibuten. Following dosing, ceftibuten undergoes isomerization to trans-ceftibuten; approximately 10% of ceftibuten is converted to the trans-ceftibuten isomer, which has about one-eighth the antimicrobial potency of the cis-ceftibuten isomer (<xref rid="B1" ref-type="bibr">1</xref>). Consistent with the known pharmacokinetic characteristics of ceftibuten, in our study, cis-ceftibuten was the predominant isomer in plasma; exposures of the trans-ceftibuten isomer represented &lt;10% of the total exposure. The current findings generally align with the prior studies of single and multiple doses of ceftibuten 400 mg. After a single dose, mean cis-ceftibuten area under the curve (AUC) has been reported as 73.7&#8211;95.3 &#181;g&#8226;h/mL, <italic toggle="yes">C</italic><sub>max</sub> as 15.0&#8211;17.6 &#181;g/mL, <italic toggle="yes">T</italic><sub>max</sub> as 2.0&#8211;2.6 hours, and <italic toggle="yes">t</italic><sub>1/2</sub> as 2.3&#8211;2.5 hours (<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">&#8211;</xref><xref rid="B12" ref-type="bibr">12</xref>). After multiple doses (8&#8211;10 days) of ceftibuten 400 mg bid, mean cis-ceftibuten AUC has been reported as 97.1&#8211;118.6 &#956;g&#8226;h/mL, <italic toggle="yes">C</italic><sub>max</sub> as 20.6&#8211;21.7 &#181;g/mL, <italic toggle="yes">T</italic><sub>max</sub> as 2.3&#8211;2.4 hours, and <italic toggle="yes">t</italic><sub>1/2</sub> as 2.4&#8211;3.1 hours (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Plasma protein binding was also similar to previously reported values (<xref rid="B1" ref-type="bibr">1</xref>). Dose proportionality was observed for AUC but was less than dose proportional for <italic toggle="yes">C</italic><sub>max</sub>, following single doses of 400&#8211;1,200 mg. Loss of dose proportionality has been observed for ceftibuten <italic toggle="yes">C</italic><sub>max</sub> and AUC when doses greater than 400 mg are administered, suggesting that absorption may be saturated in the proximal gastrointestinal tract (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>).</p><p>The absolute bioavailability of ceftibuten is unknown; however, measurements of cis-ceftibuten in urine following 400 mg dose(s) suggest at least 50% bioavailability (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). Total urinary recovery within 24 hours of the administered cis-ceftibuten dose in this study was approximately 47% in the 1,200 mg cohort. Urinary excretion was not measured in lower dose cohorts and prevents direct comparison to previous studies. In one recent study, urinary recovery of cis-ceftibuten was 83% and 87% following single doses of ceftibuten 400 and 600 mg, respectively, but was 64% after a single dose of ceftibuten 800 mg (<xref rid="B10" ref-type="bibr">10</xref>). The lower urinary recovery of 47% following a single dose of ceftibuten 1,200 mg in the current study may be due in part to a shorter collection period relative to the study by Hern&#225;ndez-Mitre et al. (collection over 24 hours versus 48 hours) (<xref rid="B10" ref-type="bibr">10</xref>). In a study by Bressolle et al., in which participants received ceftibuten 400 mg q12h for 7 days, urinary recovery of cis-ceftibuten was 58% following a single dose of ceftibuten and a 12-hour collection period and increased to 63% following the day 8 dose and a 48-hour collection period (<xref rid="B9" ref-type="bibr">9</xref>). In addition, lower recovery at a 1,200 mg dose might reflect an elimination pathway that is subject to saturation at higher doses (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>).</p><p>In conclusion, this study in healthy adults demonstrated that higher doses of ceftibuten were safe and well tolerated. Ceftibuten is a highly bioavailable oral cephalosporin, and the pharmacokinetic profile at higher doses is favorable and supports the higher doses required to treat drug-resistant Enterobacterales infections. This study supports the continued evaluation of ceftibuten&#8211;ledaborbactam etzadroxil as an oral treatment for serious infections, includingcUTI.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4-1"><title>Study design</title><p>This phase 1, two-period, randomized, double-blind, placebo-controlled, sequential-group, ascending dose study of ceftibuten administered orally for 10 days in healthy adults was conducted at a single site (PRA Health Sciences; Groningen, The Netherlands). The study protocol was reviewed and approved by an institutional review board, and the study was done in accordance with the ethical principles that have their origin in the Declaration of Helsinki, with the International Council for Harmonisation Guideline for Good Clinical Practice, and with all applicable regulatory requirements. All participants provided written informed consent before being screened. The study is registered on ClinicalTrials.gov (<ext-link xlink:href="https://clinicaltrials.gov/study/NCT04314206?term=NCT04314206&amp;rank=1" ext-link-type="uri">NCT04314206</ext-link>).</p><p>Eligible participants were randomized at a 3:1 ratio to receive ceftibuten or placebo. Participants were enrolled in one of three cohorts; each cohort comprised 12 participants, nine randomized to ceftibuten and three randomized to placebo. Within each cohort, a single oral dose was administered on day 1 (single-dose period), followed by a 1-day washout period and 10 days of repeated oral doses (days 3&#8211;12; multiple-dose period). Participants in the 400 mg cohort received a single dose of ceftibuten 400 mg or placebo during the single-dose period and ceftibuten 400 mg or placebo once daily during the multiple-dose period. Participants in the 800 mg cohort received a single dose of ceftibuten 800 mg or placebo during the single-dose period and ceftibuten 400 mg every 12 hours (q12h; total daily dose 800 mg) or placebo during the multiple-dose period. Participants in the 1,200 mg cohort received ceftibuten 1,200 mg or placebo during the single-dose period and ceftibuten 400 mg q8h (total daily dose 1,200 mg) or placebo during the multiple-dose period. On day 12, participants in the 400 mg q12h and 400 mg q8h cohorts received only a single morning dose.</p><p>After completion of the 400 and 800 mg cohorts, a safety monitoring committee reviewed all available blinded safety data before the decision was made to begin dosing in the 1,200 mg cohort.</p></sec><sec id="s4-2"><title>Participants</title><p>Healthy men and nonpregnant women, 18&#8211;55 years of age, with a body mass index of &#8805;18.5 kg/m<sup>2</sup> and &#8804;30.0 kg/m<sup>2</sup> and normal vital signs, hematology, and clinical chemistry values were eligible to enroll. Key exclusion criteria were regular use of medication for a chronic condition, history of drug allergy requiring urgent medical treatment, hypersensitivity to a &#946;-lactam antibacterial drug, positive drug screen, confirmed or suspected COVID-19 infection, or positive screening tests for hepatitis B surface antigen, anti-hepatitis C virus antibodies, or anti-human immunodeficiency virus 1 or 2 antibodies. Participants were required to discontinue any medications, vitamins, supplements, nicotine, and vaping products at least 14 days prior to dosing; exceptions were acetaminophen at doses &#8804; 3 g/day and hormonal contraceptives.</p></sec><sec id="s4-3"><title>Assessments</title><p>Safety was assessed via ongoing monitoring of adverse events and changes in physical examination findings, clinical laboratory measures, vital signs, and ECGs. For determination of single-dose and steady-state plasma pharmacokinetics of cis- and trans-ceftibuten, serial blood samples were collected pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, and 24 hours after the day 1 dose; pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 (400 mg daily and 400 mg q12h cohorts), and 16 hours (400 mg daily cohort) after the day 3 dose; pre-dose on days 4, 6, 8, and 10; and pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, and 24 hours after the day 12 dose. Additional blood samples were collected at 2, 4, and 8 hours post-dose on days 1 and 12 for the evaluation of cis-ceftibuten and trans-ceftibuten protein binding. For assessment of cis-ceftibuten and trans-ceftibuten urine pharmacokinetics, urine samples were collected within 12 hours before the day 1 dose; all urine was collected predose and for 24 hours following dosing on days 1 and 12.</p></sec><sec id="s4-4"><title>Sample collection and analysis</title><p>For plasma pharmacokinetics and protein binding assays, 6 (pharmacokinetics analyses) or 10 mL (protein binding) blood was collected in prelabeled, prechilled 6 or 10 mL K<sub>2</sub>EDTA collection tubes (BD Biosciences). Tubes were inverted 8&#8211;10 times, placed on ice, centrifuged for 10 minutes at 1,000 &#215; <italic toggle="yes">g</italic> at 4&#176;C, and stored &#8804;60 minutes after sample collection at &#8211;70&#176;C or lower. For urine pharmacokinetics assays, urine samples comprised 2 mL of the total urine volume collected from participants during each collection period. Urine samples were transferred into a prechilled 15 mL conical storage tube (ThermoFisher Scientific) and stored upright, &#8804;120 minutes after the end of each collection period, at &#8211;70&#176;C or lower.</p><p>Plasma and urine samples were assayed for cis-ceftibuten and trans-ceftibuten using bioanalytical methods that met all validation criteria for accuracy, precision, and bias. Liquid chromatography&#8211;tandem mass spectrometry (LC&#8211;MS/MS) was used to analyze plasma samples for cis-ceftibuten using a calibration standard of 0.150&#8211;75.0 ug/mL based on the analysis of 0.100 mL of mixed matrix plasma, and for trans-ceftibuten using a calibration standard of 8.00&#8211;4,000 ng/mL based on the analysis of 0.100 mL of mixed matrix plasma. Mixed matrix plasma containing cis-ceftibuten and trans-ceftibuten and the internal standard <sup>13</sup>C<sub>3</sub>,<sup>15</sup>N<sub>2</sub>-ceftibuten (a mixture of cis-ceftibuten and trans-isomers) was extracted using protein-precipitate plus lipid filter and analyzed using Sciex API 5000 LC-MS/MS with an HPLC column. The peak area of the <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 411.3 &#8594; 268.1 cis-ceftibuten and trans-ceftibuten product ion was measured against the peak area of the <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 416.0 &#8594; 273.0 <sup>13</sup>C<sub>3</sub>,<sup>15</sup>N<sub>2</sub>-cis-ceftibuten and <sup>13</sup>C<sub>3</sub>,<sup>15</sup>N<sub>2</sub>-trans-ceftibuten internal standard product ion. Quantitation used a weighted 1/x<sup>2</sup> linear least-squares regression analysis generated from calibration standards that were prepared on the day of extraction.</p><p>Plasma protein binding for cis- and trans-ceftibuten was determined using ultracentrifugation and assays for total and unbound concentrations.</p><p>LC&#8211;MS/MS was used to analyze urine samples for cis-ceftibuten using a calibration standard of 0.0600&#8211;30.0 ug/mL based on the analysis of 0.200 mL of urine, and for trans-ceftibuten using a calibration standard of 3.00&#8211;1,500 ng/mL based on the analysis of 0.200 mL of urine.</p><p>The characteristics of the bioanalytical assays for cis- and trans-ceftibuten in plasma and urine are provided in <xref rid="SuF1" ref-type="supplementary-material">Table S2</xref>.</p></sec><sec id="s4-5"><title>Pharmacokinetic and statistical analyses</title><p>The plasma PK samples collected on days 1, 3, and 12 were used to generate full pharmacokinetic profiles; the remaining plasma pharmacokinetic samples were used to determine trough plasma pharmacokinetic samples prior to dosing on days 4, 6, 8, 10, and 12. Plasma and urine pharmacokinetic parameters were calculated using noncompartmental analysis of the plasma and urine concentration&#8211;time data for cis-ceftibuten and trans-ceftibuten (Certara WinNonlin, Radnor, PA). Urine samples were analyzed for the 1,200 mg cohort only.</p><p>Single-dose plasma pharmacokinetic parameters were determined in the single-dose period, and both single-dose (day 1) and multiple-dose (day 12) pharmacokinetic parameters were determined in the multiple-dose period. Estimated pharmacokinetic parameters included <italic toggle="yes">C</italic><sub>max</sub>, time to <italic toggle="yes">C</italic><sub>max</sub> (<italic toggle="yes">T</italic><sub>max</sub>), AUC<sub>tau</sub>, AUC<sub>inf</sub>, <italic toggle="yes">t</italic><sub>1/2</sub>, CL/F, <italic toggle="yes">V</italic>z, F<sub>e</sub>, and CL<sub>R</sub>. For multiple-dose regimens, the accumulation ratio (R<sub>ac</sub>) was calculated as AUC<sub>tau</sub> day 12 (steady state)/AUC<sub>tau</sub> day 3 (first dose). The actual sample times were used to calculate the pharmacokinetic parameters. Calculation of <italic toggle="yes">&#955;</italic><sub>Z</sub> was based on the best fit of concentrations in the observed terminal elimination phase of a profile, and statistical inclusion of any parameter based on <italic toggle="yes">&#955;</italic><sub>Z</sub> required the goodness-of-fit statistic (<italic toggle="yes">R</italic><sup>2</sup>) to be greater than 0.8. Dose proportionality based on <italic toggle="yes">C</italic><sub>max</sub> and AUC were compared across dose levels on days 1 and 12. Dose proportionality was determined via linear regression analysis using the following formula: ln(PK) = ln(&#946;0) + &#946;1 ln(Dose) + &#949;, for which PK was the pharmacokinetic parameter tested (e.g., <italic toggle="yes">C</italic><sub>max</sub> or AUC), ln(&#946;0) was the <italic toggle="yes">y</italic> intercept, &#946;1 was the slope, and &#949; was an error term. A slope with a 90% CI containing 1 indicated linearity or dose proportionality. Dose proportionality was assessed for the single-dose period only, as all cohorts received a single 400 mg morning dose of ceftibuten on day 12 of the multiple-dose period.</p><p>As per protocol, urine samples were analyzed for only the 1,200 mg cohort, a higher dose than those for which urine PK data have not previously been reported. Urinary analyses determined the amount of cis-ceftibuten and trans-ceftibuten excreted in urine over time, the percentage eliminated renally, and an estimate of renal clearance (CL<sub>R</sub>).</p><p>Pharmacokinetic parameters were analyzed for all participants who received at least one dose of study drug and had evaluable pharmacokinetic parameters for the single-dose or multiple-dose periods. Adverse events and other safety parameters were summarized using descriptive statistics for all participants who received at least one dose of study drug in the single-dose or multiple-dose periods. Continuous variables were summarized using descriptive statistics by treatment, including <italic toggle="yes">n</italic>, arithmetic mean, standard deviation, median, and range. For pharmacokinetic data, the coefficient of variation (%CV), geometric mean, and geometric CV were also calculated.</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank the participants in the trial. Autumn Kelly and Donna Simcoe of Simcoe Consultants Inc. provided writing assistance based on author guidance.</p><p>The study reported herein was funded by Venatorx Pharmaceuticals, Inc., and in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C.</p><p>M.B.D.: visualization; writing&#8212;original draft; writing&#8212;review and editing. H.C.: visualization; writing&#8212;review and editing. C.F.O.: visualization; writing&#8212;original draft; writing&#8212;review and editing. K.L.: data curation; project administration; supervision; writing&#8212;review and editing. P.S.: data curation; formal analysis; methodology; project administration; supervision; writing&#8212;review and editing. G.W.: formal analysis; writing&#8212;review and editing. P.C.M.: data curation; formal analysis; methodology; project administration; supervision; visualization; writing&#8212;original draft; writing&#8212;review and editing. J.W.: investigation; supervision; writing&#8212;review and editing. All authors reviewed the manuscript, approved the final version, and agreed to be accountable for all aspects of the work.</p></ack><sec sec-type="ethics" id="s5-1"><title>ETHICS APPROVAL</title><p>The clinical study protocol, informed consent forms, and other study documents were reviewed and approved by the Independent Ethics Committee (IEC) of the foundation &#8220;Beoordeling Ethiek Biomedisch Onderzoek&#8221; (English translation: &#8220;Evaluation of Ethics in Biomedical Research&#8221;) (Doctor Nassaulaan 10, 9401 HK Assen, The Netherlands).</p></sec><sec sec-type="supplementary-material" id="s5-2"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/aac.00087-25" ext-link-type="uri">https://doi.org/10.1128/aac.00087-25</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.00087-25.SuF1</object-id><label>Supplemental tables</label><caption><title>aac.00087-25-s0001.docx</title><p>Tables S1 and S2.</p></caption><media xlink:href="aac.00087-25-s0001.docx" position="float" orientation="portrait"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>CEDAX (ceftibuten)</collab></person-group>. <year>2010</year>. <article-title>Pernix Therapeutics</article-title>.<source>LLC</source><publisher-loc>Gonzales, LA</publisher-loc></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>ISOCEF (ceftibuten) [summary of product characteristics]</collab></person-group>. <year>2007</year>. <article-title>RECORDATI Industria Chimica e Farmaceutica S.p.A</article-title>. <publisher-loc>Milan, Italy</publisher-loc></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Logan</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Weinstein</surname><given-names>RA</given-names></string-name></person-group>. <year>2017</year>. <article-title>The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace</article-title>. <source>J Infect Dis</source><volume>215</volume>:<fpage>S28</fpage>&#8211;<lpage>S36</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiw282</pub-id><pub-id pub-id-type="pmid">28375512</pub-id><pub-id pub-id-type="pmcid">PMC5853342</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Antimicrobial Resistance</surname><given-names>C</given-names></string-name></person-group>. <year>2022</year>. <article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>Lancet</source><volume>399</volume>:<fpage>629</fpage>&#8211;<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>European Committee on Antimicrobial Susceptibility Testing</collab></person-group>. <year>2024</year>. <article-title>Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0</article-title>. <ext-link xlink:href="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf" ext-link-type="uri">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf</ext-link>.</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karlowsky</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hackel</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sahm</surname><given-names>DF</given-names></string-name></person-group>. <year>2022</year>. <article-title>In vitro activity of Ceftibuten/VNRX-5236 against urinary tract infection isolates of antimicrobial-resistant Enterobacterales</article-title> . <source>Antimicrob Agents Chemother</source><volume>66</volume>:<elocation-id>e0130421</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01304-21</pub-id><pub-id pub-id-type="pmid">34662183</pub-id><pub-id pub-id-type="pmcid">PMC8765315</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karlowsky</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wise</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Hackel</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Pevear</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Moeck</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sahm</surname><given-names>DF</given-names></string-name></person-group>. <year>2022</year>. <article-title>Ceftibuten-ledaborbactam activity against multidrug-resistant and extended-spectrum-&#946;-lactamase-positive clinical isolates of Enterobacterales from a 2018&#8211;2020 global surveillance collection</article-title> . <source>Antimicrob Agents Chemother</source><volume>66</volume>:<elocation-id>e0093422</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/aac.00934-22</pub-id><pub-id pub-id-type="pmid">36286518</pub-id><pub-id pub-id-type="pmcid">PMC9664860</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barr</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Radwanski</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Symchowicz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Affrime</surname><given-names>M</given-names></string-name></person-group>. <year>1991</year>. <article-title>The pharmacokinetics of ceftibuten in humans</article-title>. <source>Diagn Microbiol Infect Dis</source><volume>14</volume>:<fpage>93</fpage>&#8211;<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0732-8893(91)90096-x</pub-id><pub-id pub-id-type="pmid">2013216</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bressolle</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Galtier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kinowski</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Goncalves</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Edno</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Panis</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gomeni</surname><given-names>R</given-names></string-name></person-group>. <year>1994</year>. <article-title>Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers</article-title>. <source>J Pharm Sci</source><volume>83</volume>:<fpage>1236</fpage>&#8211;<lpage>1240</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jps.2600830910</pub-id><pub-id pub-id-type="pmid">7830237</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hern&#225;ndez-Mitre</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Wallis</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Dudley</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Loutit</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Griffith</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></string-name></person-group>. <year>2024</year>. <article-title>A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects</article-title>. <source>Antimicrob Agents Chemother</source><volume>68</volume>:<elocation-id>e0109923</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/aac.01099-23</pub-id><pub-id pub-id-type="pmid">38059635</pub-id><pub-id pub-id-type="pmcid">PMC10777847</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Radwanski</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Affrime</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cayen</surname><given-names>MN</given-names></string-name></person-group>. <year>1995</year>. <article-title>Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers</article-title>. <source>Antimicrob Agents Chemother</source><volume>39</volume>:<fpage>356</fpage>&#8211;<lpage>358</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.39.2.356</pub-id><pub-id pub-id-type="pmid">7726497</pub-id><pub-id pub-id-type="pmcid">PMC162542</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Radwanski</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Marco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Affrime</surname><given-names>M</given-names></string-name></person-group>. <year>1995</year>. <article-title>Pharmacokinetics and dose proportionality of ceftibuten in men</article-title>. <source>Antimicrob Agents Chemother</source><volume>39</volume>:<fpage>359</fpage>&#8211;<lpage>361</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.39.2.359</pub-id><pub-id pub-id-type="pmid">7726498</pub-id><pub-id pub-id-type="pmcid">PMC162543</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>